Abbisko Cayman (HKSE:02256) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02256 Abbisko Cayman Ltd HKSE:02256
56 GF Score
Price HK$10.54
GF Value HK$12.30
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Abbisko Cayman FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:02256
56GF Score
Abbisko Cayman Ltd HKSE:02256
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Abbisko Cayman (HKSE:02256) Overvalued in 2026?

Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued. The current stock price of HK$10.54 is trading 14.3% below its estimated GF Value™ of HK$12.30. GuruFocus considers Abbisko Cayman to be Modestly Undervalued.

Key valuation signals for HKSE:02256:

  • FFO:
  • GF Value™: HK$12.30 vs. price of HK$10.54 (14.3% below fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the HKSE:02256 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abbisko Cayman Business Description

Other Exchanges 8ZD:Germany
Address Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
56GF Score

Get the complete analysis for HKSE:02256

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$10.54
Price
HK$12.30
GF Value